PMID- 27488211
OWN - NLM
STAT- MEDLINE
DCOM- 20171019
LR  - 20211204
IS  - 1875-5739 (Electronic)
IS  - 1567-2026 (Print)
IS  - 1567-2026 (Linking)
VI  - 13
IP  - 4
DP  - 2016
TI  - Erythropoietin and mTOR: A "One-Two Punch" for Aging-Related Disorders 
      Accompanied by Enhanced Life Expectancy.
PG  - 329-340
AB  - Life expectancy continues to increase throughout the world, but is accompanied by 
      a rise in the incidence of non-communicable diseases. As a result, the benefits 
      of an increased lifespan can be limited by aging-related disorders that 
      necessitate new directives for the development of effective and safe treatment 
      modalities. With this objective, the mechanistic target of rapamycin (mTOR), a 
      289-kDa serine/threonine protein, and its related pathways of mTOR Complex 1 
      (mTORC1), mTOR Complex 2 (mTORC2), proline rich Akt substrate 40 kDa (PRAS40), 
      AMP activated protein kinase (AMPK), Wnt signaling, and silent mating type 
      information regulation 2 homolog 1 (Saccharomyces cerevisiae) (SIRT1), have 
      generated significant excitement for furthering novel therapies applicable to 
      multiple systems of the body. Yet, the biological and clinical outcome of these 
      pathways can be complex especially with oversight of cell death mechanisms that 
      involve apoptosis and autophagy. Growth factors, and in particular erythropoietin 
      (EPO), are one avenue under consideration to implement control over cell death 
      pathways since EPO can offer potential treatment for multiple disease entities 
      and is intimately dependent upon mTOR signaling. In experimental and clinical 
      studies, EPO appears to have significant efficacy in treating several disorders 
      including those involving the developing brain. However, in mature populations 
      that are affected by aging-related disorders, the direction for the use of EPO to 
      treat clinical disease is less clear that may be dependent upon a number of 
      factors including the understanding of mTOR signaling. Continued focus upon the 
      regulatory elements that control EPO and mTOR signaling could generate critical 
      insights for targeting a broad range of clinical maladies.
FAU - Maiese, Kenneth
AU  - Maiese K
AD  - Cellular and Molecular Signaling, Newark, New Jersey 07101, USA. 
      wntin75@yahoo.com.
LA  - eng
GR  - R01 NS053946/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Neurovasc Res
JT  - Current neurovascular research
JID - 101208439
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (EPO protein, human)
RN  - 11096-26-7 (Erythropoietin)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Adaptor Proteins, Signal Transducing/*metabolism
MH  - Animals
MH  - Erythropoietin/*metabolism
MH  - Humans
MH  - *Life Expectancy
MH  - Signal Transduction/*physiology
MH  - TOR Serine-Threonine Kinases/*metabolism
PMC - PMC5079807
MID - NIHMS807750
COIS- The authors declare no conflict of interest.
EDAT- 2016/10/26 06:00
MHDA- 2017/10/20 06:00
PMCR- 2016/10/25
CRDT- 2016/08/05 06:00
PHST- 2016/06/10 00:00 [received]
PHST- 2016/07/12 00:00 [revised]
PHST- 2016/07/14 00:00 [accepted]
PHST- 2016/10/26 06:00 [pubmed]
PHST- 2017/10/20 06:00 [medline]
PHST- 2016/08/05 06:00 [entrez]
PHST- 2016/10/25 00:00 [pmc-release]
AID - CNR-EPUB-77458 [pii]
AID - 10.2174/1567202613666160729164900 [doi]
PST - ppublish
SO  - Curr Neurovasc Res. 2016;13(4):329-340. doi: 10.2174/1567202613666160729164900.